it is possible that HIV longevity gains were cost-effective, whether patients would overspend because of moral hazard, and whether the new HIV treatment technologies coverage constitutes high or low marginal value.

This is how the question was framed by the professor

prepare a memorandum whether it is possible that HIV longevity gains were cost-effective, whether patients would overspend because of moral hazard, and whether the new HIV treatment technologies coverage constitutes high or low marginal value.